Frias 2023 — Cagrilintide plus Semaglutide in Type 2 Diabetes

The Lancet·June 24, 2023

Juan P. Frias, Tina Vilsbøll, Melanie J. Davies, et al.

Summary

CagriSema improved glycemic measures and produced greater weight loss than either semaglutide or cagrilintide alone in the phase 2 setting.

Study Details

Study Design

Randomized phase 2 trial

Indication

Type 2 diabetes

Intervention

Cagrilintide plus semaglutide vs semaglutide or cagrilintide comparators

Species

Human

Sample Size

92 subjects

Risk of Bias Assessment

Sponsor-funded; combination therapy study